Background: The American Board of Internal Medicine Foundation's Choosing Wisely initiative aims to reduce unnecessary advanced imaging for early-stage breast cancer (ESBC). Additionally, NCCN Clinical Practice Guidelines in Oncology for Breast Cancer permit such images when oncologists perceive clinical clues of advanced disease. The utility of advanced imaging in ESBC is not known.
Background
The high costs of oncology care have refocused efforts to identify and reduce the processes of care that are considered of low value. In particular, ASCO recently participated in the American Board of Internal Medicine (ABIM) Foundation's Choosing Wisely initiative to identify a list of 5 health care processes that should prompt discussions between clinicians and patients regarding the value of that service. 1 One of the measures in this initiative addressed lowvalue radiologic services in early-stage breast cancer (ESBC), stating, "Don't perform PET, CT, and radionuclide bone scans in the staging of early breast cancer at low risk for metastasis." 1 For these recommendations, the Choosing Wisely initiative defines early-stage disease as stage IIb or lower.
The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Breast Cancer ask clinicians to "consider" advanced imaging for worrisome signs or symptoms of early-stage disease, similarly defined. 2, 3 These 2 recommendations differ in their wording, and may be confusing to clinicians who are weigh-ing "consider" from the NCCN Guidelines with "do not" from ASCO's Choosing Wisely recommendations.
Caution regarding regular radiologic scanning of ESBC originates from an evidence base and subsequent consensus-based recommendations that highlight the limited efficacy of advanced imaging in this population. For example, little evidence shows that advanced imaging can improve long-term survival or detection of metastatic disease in asymptomatic patients. 4 This was further demonstrated by a recent meta-analysis showing that preoperative MRI did not reduce long-term breast cancer recurrence. 5 Furthermore, increased imaging can have inadequate specificity, leading to false-positives and unnecessary invasive procedures. [6] [7] [8] For example, PET/CT has been shown to be less sensitive for the detection of axillary lymph node metastases than axillary lymph node dissection or even physical examination. 9 Finally, advanced imaging is costly and increases radiation exposure.
However, no study has examined the intersection between guideline recommendations that aim to reduce low value services and oncologists' intuition that performing these services will provide valuable information that may alter clinical management. Although some investigators have begun to describe the incidence from registry data, 10 registry data cannot adequately differentiate clinical intention and thus are insensitive to differentiating necessary from unnecessary tests. Few have closely evaluated the clinical charts to understand the clinical reasoning for why imaging was ordered. Why do oncologists order imaging in early-stage disease, and how often is this related to routine staging versus other reasons?
To answer these questions, we studied the frequency and clinical rationale for advanced imaging in patients with ESBC who had undergone diagnostic workup at a large tertiary academic cancer center. We aimed to understand the clinical utility of advanced imaging studies. Further, we sought to propose benchmarks for adherence to these guideline recommendations to form a foundation for comparison across our discipline.
Patients and Methods

Patient Selection
All patients seen at the Duke Cancer Institute with an ICD-9-CM code for a reportable breast tumor found within the tumor registry between January 1, 2010, and June 30, 2012, were included. This date range is mostly before the 2012 announcement of the ASCO Choosing Wisely measures. Patients with early-stage invasive breast cancer (≤ stage IIb) were included in the primary analysis and compared with an age-matched cohort of patients without cancer. The list of medical records was uploaded to the data warehouse tool DEDUCE for the purpose of exporting them with the selected Current Procedural Terminology (CPT) codes for CT of the brain, chest, abdomen, or pelvis; PET with or without CT; MRI of the brain; or nuclear bone scans that occurred within 60 days after diagnosis. When multiple qualifying CPT codes were found, the first code closest to the diagnosis date was selected for the analysis.
Chart Abstraction
To provide a robust sample for abstraction, we randomly selected 40% of charts for review. Two abstractors reviewed the medical charts of a sample of patients who were initially identified. Abstractions were performed by a medical oncology fellow (T.Z.) and a quality administrator with tumor registry experience (S.P.). Results of their abstractions were presented to an attending medical oncologist (A.K.), who was blinded to the identity and response of the reviewer, who also determined intent. Majority findings are reported.
Primarily, chart abstractions focused on the medical reason for ordering the imaging study in question, which providers ordered the imaging studies, and whether the results of imaging were positive for any abnormal findings. Results noted as positive were reviewed by a breast oncologist to determine whether the findings were clinically relevant and resulted in a change in clinical management. Examples of management change include significant additional follow-up tests or further biopsy procedures that significantly delayed or altered the treatment plan, or modification of the treatment regimen (eg, chemotherapy, hormonal therapy) altogether.
When multiple images were ordered on the same date, the abstracters reviewed the overall intent of the portfolio of images ordered to determine appropriateness.
Comparison Versus Controls
To obtain a baseline rate of the performance of advanced imaging in noncancer populations, we compared our findings with 2 age-matched control populations, which were patients without a primary diagnosis of any malignancy evaluated at Duke University. These time periods were randomly selected from the time period of the study. The first population was from June 1 to July 30, 2011; the second from December 1, 2011, to January 31, 2012. This comparison was performed to account for baseline rates of imaging performed in general populations for noncancer indications, such as infections or trauma.
Statistical Analysis
Basic descriptive statistics were calculated for this study. For the comparison of frequency of image ordering between patients with cancer and the noncancer control population, a chi-square test was performed. Univariate logistic regression was used to determine patient and disease characteristics associated with the ordering of imaging. For determination of the attribute agreement between the 2 chart abstractors, a k statistic was calculated. All analyses were performed using JPM Statistical Software (SAS Institute, Cary, NC).
Results
A total of 1,143 patients with ESBC were evaluated. Most patients were white, older than 50 years, and had private insurance as the primary payer. A total of 250 patients (21.8%) had at least one advanced imaging study (including chest CT, abdomen/pelvis CT, brain CT, brain MRI, PET/CT, and nuclear bone scan) performed in the first 60-day period after diagnosis. Of those who received an advanced imaging study, 58 (23%) had 1, 88 (35%) had 2, and 104 (42%) had 3 or more studies performed. Patients who underwent advanced imaging were more likely to be hormone receptor-negative, triple-negative, and younger (age <50 years), and have higher stage disease (stage IIb vs ≤ stage IIa; all P<.001) ( Table 1) .
Two age-matched control cohorts of 1,142 patients without cancer, all seen at Duke University Hospital, were selected. Of the patients without cancer in the June to July cohort, 47 advanced imaging studies were performed on 42 patients (3.7%); 5 patients had 2 imaging studies each. Of the patients without cancer selected in the December to January cohort, 51 procedures were performed on 36 patients (3.2%); 11 of these patients had multiple imaging studies, including one patient who had 4 imaging studies ordered during this 60-day period.
Comparing patients in our analysis to noncancer controls, a statistically significant higher frequency of advanced imaging was seen between the cancer and noncancer cohorts (21.8% vs 3.7%; P<.0001). There was no seasonal difference in the frequency of advanced imaging when comparing patients with and without cancer in either of the 2 noncancer cohorts. Manual chart abstraction was performed on 95 of the 250 patients (38%) who had advanced imaging studies. Clinical reasoning for obtaining the scans was abstracted (Figure 1) . Routine staging without documentation of any worrisome findings was the reason for radiologic images being ordering for 59 of these patients (62%). A total of 20 patients (22%) had symptoms or concerning physical examination findings prompting the imaging study, and 16 other patients (17%) had a concurrent disease (eg, history of ovarian cancer, sarcoidosis with chest involvement) warranting the imaging study. Of the 59 patients who had scans obtained for routine staging purposes, 9 (15%) had a significant abnormal finding related to the underlying cancer, which resulted in a change in clinical management. Combined, the patients who had a clinical reason for their imaging study and those who had abnormal results found on staging scans accounted for 45% of the abstracted cases.
The manual chart abstraction also captured the type of clinical provider who ordered the advanced imaging studies (Figure 2 ). Of the 95 cases, advanced imaging was ordered by the medical oncologist in 55 (58%), a surgical oncologist in 27 (28%), an emergency physician in 8 (8%), and a radiation oncologist in 1 (1%), and 4 scans (4%) were ordered by other types of physicians.
Of the 95 reviewed studies, there were discrepancies in the abstractor-determined reasons for ordering the scan in 35 cases (36.8%), for a k statistic of 0.26. On review by a breast oncologist, 24 of the cases included clinical nuances between typical and atypical findings in ESBC not easily adjudicated through administrative data review. Sample discrepancies included "bilateral disease, atypical presentation," "bilateral breast cancer, history of Hodgkin lymphoma," "atypical due to medial location," "sclerotic lesion on chest x-ray atypical in ESBC," and "suspected concurrent ovarian neoplasm." Of the imaging studies performed in the emergency room, the predominant reason was to "evaluate for syncope and fall." These details required careful, manual review of the medical chart and could not be described from administrative data alone.
Discussion
We found that approximately one-fifth of patients with ESBC received an advanced radiologic image within 60 days of diagnosis. Imaging was more often performed in patients who were younger, had triplenegative cancer subtype, or had higher-stage disease (eg, stage IIb). Most imaging studies were ordered by medical oncologists and were not part of an extended preoperative evaluation by surgical oncologists.
These findings further add to a growing body of evidence regarding incidence of advanced imaging in ESBC that is inconsistent. For example, Simos et al 11 recently reported a rate as high as 85% for advanced imaging based on a single-institution experience of 200 patients. 11 The same authors performed a larger, province-wide registry analysis of patients in Ontario, finding a rate of 89%. 12 Notably, these studies included patients with stage III breast cancer, demonstrating a similar odds ratio for more advanced disease stage, for which imaging is recommended, compared with stage II. Hahn et al 13 re- cently reported the experience of 2 large integrated health systems in the Western United States that actively use clinical decision support regarding imaging directly in their electronic health records. The authors found a remarkably low rate at 8% overall in a large cohort of patients with stage 0-IIb disease, with approximately half of images ordered due to physical findings concerning for advanced disease. These early data since the 2012 publication of the ASCO Choosing Wisely measures collectively reflect that important differences may exist with regard to imaging frequency as related to practice location and organization type. Further, they highlight the need to establish data-driven benchmarks to separate low and high performers when evaluating the use of advanced imaging.
Both the ASCO Choosing Wisely initiative and NCCN Guidelines aim to maximize high-value care while reducing (but not necessarily eliminating) low value services that do not improve outcomes important to patients, caregivers, or oncology professionals. Practice guidelines in general naturally spark conversations among clinical decision-makers; Choosing Wisely is one of the first large-scale initiatives to engage patients within these discussions. Others have previously demonstrated that oncology clinicians are familiar with and generally agree with the recommendation against advanced imaging in all patients with ESBC, yet 95% believe that exceptions should be made for suspicious history or clinical examination findings.
14 Further, most patients with breast cancer prefer to have radiologic imaging performed, with 70% indicating in a survey that they would feel "uncomfortable" if their physician did not order imaging. 15 When assessing the use of imaging studies, these factors should be weighed when determining value.
Through a careful analysis of associated clinical documentation, our data support that performing imaging in patients with ESBC occasionally provides clinical utility, and highlight the important limitations of evaluations of quality of oncology care that incorporate administrative data only. For example, without the manual chart abstraction, and relying on the tumor registry and electronic health record information alone, we would have overestimated the frequency of unnecessary imaging. Importantly, review by oncology clinicians reduced the categorization of advanced imaging as "for staging alone" from 21.8% to 12.1%, signifying that nuances regarding "intention" are often not accurately reflected in structured data sets. Similarly, Ryoo et al 16 recently reported on the Veterans Health Administration experience, drawing conclusions regarding the quality of processes of care, noting significant limitations in electronic health data in reflecting patient preferences and choices.
There are several limitations to this study. First, we report the experience of a single tertiary care academic cancer center. Second, our analysis searched only the administrative clinical databases of our main medical center, and not those of communitybased hospitals in our region; patients who had imaging performed at other regional hospitals or clinics were not captured in our search. Third, our analysis relied on reviewing the documentation of busy oncology clinicians. We suspect that justifications for imaging, such as localized pain with concerns for metastatic disease, may not have been routinely documented. Thus, we may overestimate the frequency of unwarranted imaging. Although incomplete documentation is a reality of busy clinical practice, it is important to remember that payers, regulators, and accreditors often rely solely on the written word of clinical notes to make decisions regarding appropriateness of care. Fourth, having reviewers determine whether results of advanced imaging led to clinically meaningful changes is inherently subjective, and reflective of the interpretation of clinical documentation that is reviewed.
Published clinical practice guidelines and recommendations serve to heighten clinician awareness about value-based care, limit unneeded studies or interventions, and serve as a platform to communicate the rationale of such decisions with patients. However, clinical medicine is a complex endeavor. Our data examine how clinician judgement can influence obtaining imaging studies for ESBC, and support allowing clinician flexibility for ordering advanced imaging in ESBC. As we move into an era of more efficient and quality-focused care delivery models, we must be careful to develop benchmarks that do not excessively proscribe advanced imaging in this setting. 
